Medpace slips after bookings decline
View all comments(0)
Shares of contract research organization Medpace MEDP.O fall 9.4% to $261.76 in extended trading
Co's Q1 new business awards fall 18.8% to $500 mln, with a 0.90x book-to-bill ratio, number of orders received to those fulfilled
Co's Q1 backlog decreases 2.1% to $2.85 bln
However, co reports Q1 sales and EPS above analysts' estimates - LSEG
Co posts Q1 sales of $558.6 mln, above est. of $527.2 mln
Co reports Q1 earnings of $3.67/shr vs. est. of $3.06/shr
As of last close, stock down ~13% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.